MIM PHARMA
MIM Pharma AS is a Norwegian biopharmaceutical company founded in 2013, focused on developing novel, plant-based medical solutions for diseases such as COVID-19, migraines, rhinitis, and seasonal allergies. They leverage a unique systems biology approach, incorporating advanced machine learning and natural language processing (NLP) techniques, to identify interactions between medicinal plant compounds and human proteins. MIM Pharma has published its pre-clinical and clinical trial results for its COVID-19 solution, Saliravira®, in Elsevier and holds an international patent. The company aims to make its treatments accessible and affordable globally.
MIM PHARMA
MIM Pharma AS is a Norwegian biopharmaceutical company founded in 2013, focused on developing novel, plant-based medical solutions for diseases such as COVID-19, migraines, rhinitis, and seasonal allergies. They leverage a unique systems biology approach, incorporating advanced machine learning and natural language processing (NLP) techniques, to identify interactions between medicinal plant compounds and human proteins. MIM Pharma has published its pre-clinical and clinical trial results for its COVID-19 solution, Saliravira®, in Elsevier and holds an international patent. The company aims to make its treatments accessible and affordable globally.